MetaCap

Greenland Mines (GRML) vs ImageneBio (IMA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImageneBio (IMA) has outperformed Greenland Mines (GRML) over the past year, losing 44.9% versus a loss of 87.1%. ImageneBio is the larger company by market cap ($48.8 million vs $44.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRML-87.08%IMA-44.87%
+46%-24%-94%
Nov 21, 20251 yearNov 20, 2026
GRML-99.40%IMA-91.58%
+98%-6%-109%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRML versus IMA key metrics
MetricGRMLIMA
Share price$2.99$3.92
Market cap$44.31M$48.83M
1-day change+2.75%0.00%
YTD return-79.31%-43.19%
1-year return-87.08%-44.87%
5-year return—-97.86%
EPS (TTM)$-9.74$-2.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$800.00K
Revenue growth (YoY)—-77.14%
Net income (latest FY)$-10.55M$-45.35M
Operating margin—-6056.38%
Net margin—-5668.63%
52-week high$37.00$7.60
52-week low$2.75$3.00
Distance from 52-week high-91.92%-48.42%
Analyst consensusnonenone
Avg. price target upside+3578.93%+359.18%
Average volume8.93M15.86K
Shares outstanding14.82M12.46M
Employees518
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMA has outperformed GRML by 42.2 percentage points over the past year.

About Greenland Mines

GRML stock →

Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

About ImageneBio

IMA stock →

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

GRML vs IMA FAQ

Which is bigger, Greenland Mines or ImageneBio?

ImageneBio (IMA) is larger, with a market capitalization of $48.83M compared with $44.31M for Greenland Mines (GRML).

Which stock has performed better over the past year, GRML or IMA?

IMA returned -44.87% over the past 12 months, compared with -87.08% for GRML (price return, excluding dividends). Past performance does not predict future results.

Are Greenland Mines and ImageneBio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons